Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Average Rating of “Moderate Buy” from Analysts

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has received a consensus rating of “Moderate Buy” from the six research firms that are covering the company, MarketBeat reports. Three analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $44.25.

COLL has been the subject of several recent research reports. Zacks Research cut Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 23rd. Weiss Ratings restated a “hold (c+)” rating on shares of Collegium Pharmaceutical in a report on Tuesday. Wall Street Zen upgraded Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Needham & Company LLC reissued a “buy” rating and set a $46.00 price target on shares of Collegium Pharmaceutical in a research report on Tuesday, October 28th. Finally, Truist Financial upped their price objective on shares of Collegium Pharmaceutical from $45.00 to $48.00 and gave the company a “buy” rating in a report on Friday, November 7th.

Collegium Pharmaceutical Price Performance

COLL traded up $1.19 on Friday, reaching $45.14. 365,481 shares of the company’s stock were exchanged, compared to its average volume of 529,884. Collegium Pharmaceutical has a twelve month low of $23.23 and a twelve month high of $48.18. The stock has a market cap of $1.43 billion, a PE ratio of 28.04 and a beta of 0.61. The company has a debt-to-equity ratio of 2.71, a current ratio of 1.36 and a quick ratio of 1.27. The stock’s fifty day moving average price is $37.05 and its 200-day moving average price is $34.02.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings data on Wednesday, September 4th. The specialty pharmaceutical company reported $1.26 EPS for the quarter. Collegium Pharmaceutical had a net margin of 7.72% and a return on equity of 102.03%. The company had revenue of $135.55 million during the quarter. Sell-side analysts expect that Collegium Pharmaceutical will post 5.62 EPS for the current year.

Insider Activity at Collegium Pharmaceutical

In other news, CFO Colleen Tupper sold 30,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $40.53, for a total transaction of $1,215,900.00. Following the completion of the sale, the chief financial officer owned 126,667 shares in the company, valued at $5,133,813.51. This trade represents a 19.15% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Thomas B. Smith sold 17,478 shares of Collegium Pharmaceutical stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $38.42, for a total transaction of $671,504.76. Following the sale, the executive vice president directly owned 70,264 shares in the company, valued at approximately $2,699,542.88. The trade was a 19.92% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 2.51% of the company’s stock.

Institutional Trading of Collegium Pharmaceutical

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Federated Hermes Inc. raised its holdings in Collegium Pharmaceutical by 67.0% in the 3rd quarter. Federated Hermes Inc. now owns 872 shares of the specialty pharmaceutical company’s stock valued at $31,000 after buying an additional 350 shares during the period. CWM LLC increased its position in shares of Collegium Pharmaceutical by 453.9% during the second quarter. CWM LLC now owns 1,407 shares of the specialty pharmaceutical company’s stock valued at $42,000 after acquiring an additional 1,153 shares during the last quarter. Hantz Financial Services Inc. raised its stake in shares of Collegium Pharmaceutical by 137.7% in the 3rd quarter. Hantz Financial Services Inc. now owns 1,714 shares of the specialty pharmaceutical company’s stock valued at $60,000 after acquiring an additional 993 shares during the period. Wealthquest Corp acquired a new position in shares of Collegium Pharmaceutical in the 1st quarter worth approximately $62,000. Finally, EverSource Wealth Advisors LLC boosted its position in shares of Collegium Pharmaceutical by 744.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,484 shares of the specialty pharmaceutical company’s stock worth $73,000 after purchasing an additional 2,190 shares during the period.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.